Browsing Tag
Merck & Co.
27 posts
Can Pfizer’s pipeline offset looming patent cliffs despite a stronger 2025 forecast?
Can Pfizer’s oncology and rare disease pipeline replace billions lost to patent cliffs? Explore how the drugmaker compares with Merck, Bristol Myers, and AstraZeneca.
Checkpoint inhibitors in early-stage cancer: A new era of adjuvant therapy is taking shape
Checkpoint inhibitors are redefining early-stage cancer care. Find out how Tecentriq, Keytruda, and others are competing for the adjuvant immunotherapy market.
HER3-DXd shows promise in treating brain metastases: Inside the TUXEDO-3 trial results from ASCO 2025
HER3-DXd from Daiichi Sankyo and Merck shows intracranial activity in CNS cancers, as TUXEDO-3 results presented at ASCO 2025 spark major oncology interest.
China just blinked: U.S. drugs spared from tariff hike—Here’s what that means
China exempts select U.S. pharmaceuticals from new 125% tariffs; firms like CSL and Merck assess supply chain resilience.
Breakthrough in ulcerative colitis treatment? Microbiotica unveils MB310 data
Microbiotica, a clinical-stage biopharmaceutical company pioneering microbiome-based therapy, has presented significant new data on MB310, its investigational treatment…
Hanmi Pharmaceutical, Beijing Hanmi progress cancer therapy BH3120 with promising trial results
Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical are making significant strides in the development of BH3120, a next-generation cancer…
Merck to acquire Curon Biopharmaceutical’s CN201 in strategic oncology expansion
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, has secured a…